Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
NCT07300839 · View on ClinicalTrials.gov ↗
Study Summary
This study is designed to find out how well the COVID-19 vaccine protects people 50 to 64, who don't have any serious health problems, compared to a group that receives a vaccine that doesn't contain an ingredient to protect against COVID-19 (placebo).
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL BNT162b2 Vaccine
Study Locations (20)
Alabama
- Pinnacle Research Group, LLC — Anniston
- North Alabama Research Center — Athens
- Simon Williamson Clinic / Synexus Clinical Research US, Inc. — Birmingham
- Accel Research Sites - Birmingham Clinical Research Unit — Birmingham
- Cullman Clinical Trials — Cullman
- AMR Clinical — Daphne
- Medical Affiliated Research Center — Huntsville
- AMR Clinical — Mobile
Arizona
- Chandler Clinical Trials — Chandler
- Synexus Clinical Research US, Inc. — Phoenix
- Scottsdale Clinical Trials — Scottsdale
- Epic Medical Research-Sun City — Sun City
- Noble Clinical Research — Tucson
- Synexus Clinical Research US, Inc./Orange Grove Family Practice — Tucson
California
- Anaheim Clinical Trials, LLC — Anaheim
- Velocity Clinical Research, Chula Vista — Chula Vista
- West Coast Research — Dublin
- Leading Edge Research LA — Encino
- Leading Edge Research — Encino
Arkansas
- Woodland International Research Group — Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25,500 participants |
| Start Date | 2025-12-10 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07300839
The ClinicalTrials.gov registry entry for NCT07300839 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 25,500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioNTech SE, which has 123 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with COVID-19 appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07300839 reports 20 study locations spanning 4 distinct geographic areas — top geographies include Alabama, Arizona, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07300839 about?
NCT07300839 is a clinical study titled "A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age". This study is designed to find out how well the COVID-19 vaccine protects people 50 to 64, who don't have any serious health problems, compared to a group that receives a vaccine that doesn't contain an ingredient to protect against COVID-19 (placebo).
What is the current status of trial NCT07300839?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 25,500 participants. The study started on 2025-12-10. Estimated completion is 2026-07-31.
What conditions does trial NCT07300839 study?
This clinical trial studies the following conditions: COVID-19, SARS-COV-2 Infection. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07300839?
The interventions under investigation include: Placebo (BIOLOGICAL), BNT162b2 Vaccine (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07300839?
This trial is sponsored by BioNTech SE, which has 123 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07300839 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.